Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Objective Tuberculosis (TB) is associated with anti–tumor necrosis factor (anti‐TNF) monoclonal antibody (mAb) therapy, but whether this association is drug‐specific remains a concern. Our objective was to describe cases of TB associated with anti‐TNF mAb therapy, identify risk factors, and estimate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis and rheumatism 2009-07, Vol.60 (7), p.1884-1894
Hauptverfasser:	Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., Bretagne, S., Emilie, D., Lemann, M., Lorthololary, O., Mariette, X.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Arthritis, Rheumatoid - drug therapy Bacterial diseases Behcet Syndrome - drug therapy Biological and medical sciences Case-Control Studies Colitis - drug therapy Diseases of the osteoarticular system Etanercept Female France Human bacterial diseases Humans Immunoglobulin G - adverse effects Immunoglobulin G - therapeutic use Infectious diseases Infliximab Life Sciences Male Medical sciences Middle Aged Prospective Studies Receptors, Tumor Necrosis Factor - therapeutic use Registries Risk Factors Spondylarthritis - drug therapy Treatment Outcome Tuberculosis - chemically induced Tuberculosis - drug therapy Tuberculosis - epidemiology Tuberculosis and atypical mycobacterial infections Tumor Necrosis Factor-alpha - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!